immutep (asx:imm) receives positive feedback from fda
Published 1 year ago • 49 plays • Length 0:21
Download video MP4
Download video MP3
Similar videos
-
5:42
immutep (asx:imm) receives fast track designation from fda
-
8:42
immutep (asx:imm) announces positive results in head and neck cancer treatment
-
6:03
immutep (asx:imm, nasdaq:immp) reports positive discussions with the fda and strong survival data
-
7:09
immutep (asx:imm, nasdaq:immp) reports 71.4% response rate for lung cancer therapy, october 31, 2023
-
16:06
immutep (asx:imm) - webinar presentation
-
5:10
immutep (asx:imm) reports first subject dosed in autoimmune disease study
-
5:19
cramer: this biotech stock could be worth over $100 billion on an fda approval
-
3:13
manila city noon at ngayon
-
7:11
calculating limits for carcinogens: ai, pde, and less than lifetime as per ich m7
-
47:53
immutep (asx:imm) tacti-003 results, june 2024
-
16:07
immutep (asx:imm) - webinar presentation
-
2:53
world antimicrobial resistance awareness week | ims & sum hospital
-
3:33
immutep (asx:imm) reports positive trial data
-
6:25
immutep (asx:imm) discusses a transformative year for lag-3 therapies
-
2:00
stocks of the hour: immutep, livehire, forbidden foods, estrella resources
-
15:49
immutep (asx:imm) - webinar presentation
-
7:17
immutep (asx:imm) delivering strong data in first-line non-small cell lung cancer
-
4:44
immutep (asx:imm) - innovative cancer therapies
-
8:19
from the helm: immutep´s (asx: imm executive director & ceo marc voigt
-
1:14:06
immutep (asx:imm) sitc 2021 results - management update
-
8:10
immutep's (asx:imm) executive director & ceo marc voigt
Clip.africa.com - Privacy-policy